Interviews
CEO Matt Gline talked to Scrip about preparing for the launch of brepocitinib in dermatomyositis, lessons learned from Vtama, and how smaller biopharmas are delivering launch successes.
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
As the Belgian firm's blockbuster beats AbbVie's Skyrizi in a head-to-head psoriatic arthritis study.
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.
The Swiss major's immunology chief Angelika Jahreis tells Scrip of her high hopes for the potential pipeline-in-a-product.
After announcing the acquisitions of Inozyme and Amicus last year, the rare disease specialist is continuing to scout out pipeline expansion opportunities.
NextGate Partners’ managing partner shares his views on the biopharma investment and dealmaking environment in South Korea, along with the particular strengths of companies in the country and R&D areas of focus for this year.
With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.
The European Life Sciences Coalition has been launched to boost investment in the sector.
The launch of Brinsupri has attracted attention, but the company also has several other late-stage opportunities. CMO Martina Flammer talked to Scrip about the pipeline.
After more than a decade developing its nanoparticle radioenhancer technology, Nanobiotix and partner Johnson & Johnson believe it could soon begin to revolutionize frontline oncology treatment.
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Scrip spoke with Novo’s SVPs for global research and global business development, Jacob Petersen and Tamara Darsow, about dealmaking and R&D priorities after the company streamlined to focus more intensely on obesity and diabetes.
Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.